New multitarget molecule designed with high potential in future treatments for Alzheimer's disease
Monday, June 4, 2012 - 15:31
in Health & Medicine
Researchers have developed a multitarget molecule, ASS234, which according to the results of in vitro studies conducted, inhibits the aggregation of the ß-amyloid protein, involved in Alzheimer's disease. At the same time, ASS234 stimulates the cholinergic and monoaminergic transmission, key factors involved in the cognitive function. In addition, ASS234 is able to cross the blood–brain barrier with an elevated multipotent profile designed on basis of donepezil (Aricept®), one of the few effective drugs in palliative and symptomatic treatments of the disease.